- Fycompa(R) (perampanel) for use as an adjunctive treatment for partial
onset seizures, with or without secondarily generalised seizures, in patients with
epilepsy aged 12 years and older
- Inovelon(R) (rufinamide) for the adjunctive treatment of seizures associated
with Lennox-Gastaut Syndrome in patients >4 years. (Inovelon was originally developed
by Novartis)
- Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients
with partial onset seizures, with or without secondary generalisation. (Zebinix is
under license from BIAL)
- Zonegran(R) (zonisamide) as monotherapy in adults and adjunctive therapy in
adults, adolescents and children aged six years and above with partial onset seizures,
with or without secondary generalisation. (Zonegran is under license from the
originator Dainippon Sumitomo Pharma)
About Eisai
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
loss
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Norway, Portugal, Russia, Slovakia, Spain, Switzerland, Sweden, the Netherlands and the Middle East.
For further information please visit our web site http://www.eisai.co.uk
References
1. Fycompa. Summary of Product Characteristics (updated November 2013) http://www.medicines.org.uk/emc/medicine... 12mg+film-coated+tablets/ [http://www.medicines.org.uk/emc/medicine... ] [ http://www.medicines.org.uk/emc/medicine... ]
2. Pfäfflin, M. und May, T. Wieviele Patienten mit Epilepsien gibt es in Deutschland und wer behandelt sie? Neurol Rehabil, 2000; 6, (2) 77-81.
3. ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010. Available at; http://www.ilae-epilepsy.org/Visitors/Documents/EUROReport16... (Accessed June 2011)
4. Brodie MJ et al, Neurology 2012; 78:1548-1554
5. Rogawski MA. Epilepsy Currents 2011;11:56-63
6. Steinhoff, B.J., et al., A multicenter survey of clinical experiences with perampanel in real life in Germany and
Austria. Epilepsy Res. (2014), http://dx.doi.org/10.1016/j.eplepsyres.2...
7. Epilepsy in the WHO European Region http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510... [Accessed 10 April 2012].
8. Pugliatti M, et al. Epilepsia 2007: 48(12) 2224 - 2233.
Date of preparation: May 2014
Job code: Perampanel-UK2157
CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson / CharlotteAndrews, +44(0)7908-314-155/+44(0)7947-231-513, Cressida_Robson@eisai.net,Charlotte_Andrews@eisai.net ; Tonic Life Communications, FrancesMurphy/Nicola Lilley, +44(0)207-798-9262 /+44(0)207-798-9905,frances.murphy@toniclc.com, nicola.lilley@toniclc.com
